DXCM DexCom Inc Stock Price & News

However, this is normal for a business in the growth stage of DXCM. These devices offer only discrete measurements at specific times, making it challenging to manage blood glucose fluctuations effectively. This system enhances care coordination and support for individuals with diabetes. The good news for DexCom is that weight loss pills do not pressure demand for its products and services. As the 2023 stock-market rally continues, this is a good time to look further ahead to see which companies are expected to show the highest growth rates through 2025. DexCom shares split on the morning of Friday, June 10th 2022.

We’d like to share more about how we work and what drives our day-to-day business. It is important to note that DexCom’s reliance on CGM technology makes m3 meaning it vulnerable to potential disruptions. However, its fair value estimate suggests upside potential, making DXCM an attractive long-term investment.

During its 2Q23 earnings call, the company revised its full-year 2023 revenue guidance, raising it to a range of $3.50 to $3.55 billion, which represents a growth rate of 20% to 22% for the year. The trend is observed across different patient populations, including those transitioning from intensive insulin to basal insulin and non-insulin users. Patients’ continuous use of CGM has remained steady over time, indicating its importance in diabetes management.

Financial Calendars

Looking at analyst expectations, the company is not expected to see slower growth in the years ahead. This is based on close to 20% annual revenue growth and an expected EBITDA margin surge from roughly 14% in 2019 to potentially more than 30% in 2025E. According to 15 analysts, the average rating for DXCM stock is “Strong Buy.” The 12-month stock price forecast is $138.07, which is an increase of 34.06% from the latest price. Keep them on track to be the S&P 500’s best October performer with a month-to-date gain of 50.6%.

• According to 15 analysts, the average rating for DXCM stock is “Strong Buy.” The 12-month stock price forecast is $138.07, which is an increase of 34.06% from the latest price.
• DXCM’s beta can be found in Trading Information at the top of this page.
• Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
• Dividend yield allows investors, particularly those interested in dividend-paying stocks,
  to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

The same for earnings is pinned at 34 cents per share, implying growth of 21.4% year over year. Accurate and effective product performance, coupled with simplicity of use, is driving adoption of new CGM devices in the company’s portfolio. DexCom stated that 8,000 physicians prescribed its CGM devices (who had previously not done so) during the second quarter.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. DXCM’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Wall Street Has Found Its Next High-Flying Stock-Split Stock. Here’s Why I’m Not Buying the Hype.

Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. Meanwhile, the company’s plan to expand its product portfolio beyond intensive insulin use will further benefit the top line going forward. DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 28.83%. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

This program has been designed for provincial people with type 1 diabetes, who are above the age of two and meet the coverage criteria. Shares of Norwegian Cruise Line and Carnival are upgraded, HP Inc. falls after Berkshire Hathaway discloses it sold 5.5 million shares, and AMC raises $325.5 million in an equity offering. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

DexCom MarketRank™ Forecast

This Zacks Rank #3 (Hold) company’s shares have fallen 7.1% year to date compared with the industry’s 4.9% decline. DexCom, Inc. (DXCM Quick QuoteDXCM – Free Report) is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further.

DexCom is on track to meet its long-term margin targets as it progresses toward 65% gross margins in the future. As diabetes is one of the health risks that come with obesity (the list below shows health risks according to the CDC), DexCom is one of the victims on the stock market. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. The Ontario government began coverage for the Dexcom G6 CGM System through the province’s Assistive Devices Program.

What’s Next For DexCom Stock After A 17% Fall In A Month?

The rally comes as maker of glucose monitoring systems reported last week that beat expectations and got a boost from the … Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning https://1investing.in/ of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

• An investor that had 100 shares of stock prior to the split would have 400 shares after the split.
• At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
• On July 24, 2023, Steven Pacelli, the Executive Vice President and Managing Director of DexCom Inc ( DXCM , Financial), sold 412 shares of the company.
• The company’s shares have rallied 13.8% year to date against the industry’s 10.3% decline.
• Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days.

Consider these nine momentum stocks that are climbing the charts this year. On July 24, 2023, Steven Pacelli, the Executive Vice President and Managing Director of DexCom Inc ( DXCM , Financial), sold 412 shares of the company. One share of DXCM stock can currently be purchased for approximately $103.86. The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%. The company continues to expand its product portfolio with the addition of new products like DexCom One and G7 sensor.

CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem. 14 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should “moderate buy” DXCM shares.

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients.

With regard to macroeconomic inflation headwinds, DexCom acknowledged pricing headwinds in the current year, with expectations of a gradual reduction in pricing pressures compared to the previous year. The company noted that third-party data from Optum’s pharmacy base indicated that the prescription of GLP-1 therapies led to an increase in CGM prescriptions. It also helps that the company sees no risks related to the weight loss pill.

The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Shares of DexCom Inc. surged 8.1% to pace the S&P 500’s premarket gainers, after the diabetes care company said it was not currently in “active discussions” regarding a merger. The stock has rallied 12.1% year to date compared with the industry’s 11.5% growth.

The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.50 billion. The company’s shares have rallied 13.8% year to date against the industry’s 10.3% decline. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company’s employees.

In order to expand its footprint even further, the company is dedicated to continual improvement. In this, I’ll walk you through the DexCom business model, its opportunities, the weight loss pills, and why we can assume that DXCM shares are roughly 40% to 50% undervalued. Over the past ten years alone, DXCM shares have returned close to 1,400%, beating its healthcare peers and the S&P 500 (SP500) by a mind-blowing margin. Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better. Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%.